Cencora (COR) to Release Earnings on Wednesday

Cencora (NYSE:COR) is expected to be posting its Q4 2025 results before the market opens on Wednesday, November 5th. Analysts expect Cencora to post earnings of $3.80 per share and revenue of $83.3559 billion for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 EPS. On average, analysts expect Cencora to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Cencora Price Performance

NYSE:COR opened at $340.74 on Tuesday. The stock has a market cap of $66.06 billion, a P/E ratio of 35.06, a PEG ratio of 1.56 and a beta of 0.63. Cencora has a one year low of $223.92 and a one year high of $350.46. The company has a fifty day moving average price of $309.14 and a 200 day moving average price of $297.57. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio is presently 22.63%.

Analyst Upgrades and Downgrades

COR has been the subject of several research analyst reports. Wells Fargo & Company upped their target price on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. UBS Group upped their target price on shares of Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Evercore ISI set a $340.00 target price on shares of Cencora in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Mizuho increased their price objective on shares of Cencora from $334.00 to $340.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $329.55.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 41,544 shares of company stock valued at $12,230,941. Corporate insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

A number of hedge funds have recently made changes to their positions in the company. Viking Global Investors LP increased its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Cencora by 228.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock worth $292,207,000 after purchasing an additional 677,952 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Cencora by 3.3% during the 2nd quarter. California State Teachers Retirement System now owns 302,083 shares of the company’s stock worth $90,580,000 after purchasing an additional 9,733 shares in the last quarter. Man Group plc increased its position in shares of Cencora by 4.3% during the 2nd quarter. Man Group plc now owns 210,180 shares of the company’s stock worth $63,022,000 after purchasing an additional 8,716 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Cencora by 1.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 163,261 shares of the company’s stock worth $48,954,000 after purchasing an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.